Stryker’s Minimally Invasive Acquisitions
For a company that has targeted minimally invasive surgical products of late, Stryker Corporation (NYSE: SYK) has been highly visible in the acquisition arena this year. It started in February 2016. That month, the medical device giant announced three deals, totaling $2.03 billion. In April, three more acquisitions were announced, with only one disclosed price of $40.6 million. Halfway through September, the company has made two more acquisitions, for undisclosed prices. For those keeping score, that’s eight deals for approximately $4.1 billion. Stryker’s most recent deals have targeted Ivy Sports Medicine, LLC for its minimally invasive meniscal repair platform, and Restore... Read More »Fresensius Helios Adds 43 Spanish Hospitals
Fresenius Helios (EXTRA: FRE.DE) was already the largest private hospital company in Europe, and now it’s grown even larger. On September 5, 2016, the company announced the acquisition of Quirónsalud, Spain’s largest private hospital operator, with 43 hospitals, 39 outpatient centers, and 300 occupational risk prevention centers. Quirónsalud was created by the 2014 merger of IDC Salud and Grupo Hospitalario Quirón. Fresenius Helios, a division of Fresenius SE & Co. KGaA, vaulted to the top of the private European hospital market in September 2013, following the its acquisition of 43 hospitals and 15 outpatient facilities in Germany, sold by Rhön Klinikum AG, for... Read More »Radiopharmacies Now on Dealmakers’ Radar
You can’t get much more “specialty” in the specialty pharmacy business than to deal in radiopharmaceuticals. Two recent deals, announced in August, show this area is heating up. IBA Molecular, a global maker and distributor of radiopharmaceutical products, agreed to pay approximately $613 million for Mallinckrodt’s (NYSE: MNK) nuclear imaging business, including a portfolio of diagnostic imaging products. The U.S. market accounts for approximately two thirds of the division’s current annual revenues. For Mallinckrodt, the sale continues its strategic portfolio transformation, as the company evolves to handle specialty pharmaceuticals that don’t glow. IBA... Read More »Third Quarter 2016 Shows Signs of Slowing
Eight months into the year is a good time to take stock of the state of the healthcare M&A market. On the whole, volume and value look to be stronger than last year. The first eight months of 2016 show a combined total of 1,019 transactions, compared with 1,005 in the same period in 2015, a 1% difference. Five of the first eight months in 2016 have posted higher transaction totals than the same months in 2015. Deal values have to be examined more closely, owing to the mega-deals that can create huge month-to-month fluctuations. Total dollars spent in the first eight months of 2016 are approximately $196 billion. In the same period in 2015, spending reached nearly $338 billion, thanks... Read More »BioClinica Changes Hands as CRO Market Heats Up
The market for contract research organizations (CROs) is hot in 2016. Fourteen deals have been announced so far this year, compared with five in all of 2015, 11 in 2014 and eight in 2013. The latest deal was announced on August 22, as JLL Partners and Water Street Healthcare Partners exited their investment in BioClinica, Inc. and the UK-based private equity firm Cinven stepped in, for an undisclosed price. The original investment for the global clinical trial management company, then trading under the NASDAQ ticker symbol BIOC, was announced on January 30, 2013, for $123 million (1.6x revenue and 11.8x EBITDA). That deal included the acquisition of medical imaging company CoreLab... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
